BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24701697)

  • 1. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
    Sridharan M; Hubbard JM; Grothey A
    Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy for metastatic colorectal cancer].
    Iwasa S; Shimada Y
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalizing therapy for colorectal cancer.
    Wong A; Ma BB
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):139-44. PubMed ID: 24025538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.
    Pohl A; Zhang W; Ning Y; Manegold PC; Lurje G; Lenz HJ
    Oncology (Williston Park); 2008 Apr; 22(4):456-62; discussion 462-3, 467-8, 474 passim. PubMed ID: 18472617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies.
    Saif MW; Kang SP; Chu E
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):11-9. PubMed ID: 17354513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New systemic frontline treatment for metastatic colorectal carcinoma.
    Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
    Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-line therapy for metastatic colorectal cancer.
    Gundgaard MG; Soerensen JB; Ehrnrooth E
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
    O'Neil BH; Goldberg RM
    Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in metastatic colorectal cancer.
    Christopoulou A
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s43-6. PubMed ID: 15655639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Colon cancer: what is new in 2004?].
    André T; Louvet C; de Gramont A
    Bull Cancer; 2004 Jan; 91(1):75-80. PubMed ID: 14975808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin: a review of approved uses.
    Stein A; Arnold D
    Expert Opin Pharmacother; 2012 Jan; 13(1):125-37. PubMed ID: 22149372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First- and second-line therapy of metastatic colorectal cancer.
    Terstriep S; Grothey A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.